Tretinoin (Topical)
all-trans-retinoic acid; Retin-A, Retin-A Micro, Renova, Altreno, Avita, Atralin
Tretinoin Topical Indications
| Indication | Approved Population | Formulation / Brand | Status |
|---|---|---|---|
| Acne vulgaris | Adults and adolescents ≥12 years (Retin-A Micro); ≥9 years (Altreno lotion) | Retin-A (cream/gel), Retin-A Micro (microsponge gel), Altreno (lotion), Avita, Atralin | FDA Approved |
| Mitigation of fine facial wrinkles (photoaging) | Adults (as adjunct to comprehensive skin care and sun avoidance) | Renova (cream 0.02%, 0.05%) | FDA Approved |
Tretinoin (all-trans-retinoic acid) is the most extensively studied topical retinoid and remains a cornerstone of acne treatment. It reduces microcomedo formation by decreasing the cohesiveness of follicular epithelial cells and increasing cell turnover, causing extrusion of existing comedones. For photoaging, the Renova formulation is indicated as an adjunctive agent for mitigation (palliation) of fine facial wrinkles — the PI explicitly states that Renova does not eliminate wrinkles, repair sun-damaged skin, reverse photoaging, or restore younger skin. Therapeutic results for acne may be noticed after 2 weeks, but more than 7 weeks are typically required for consistent beneficial effects.
Hyperpigmentation / melasma — Widely used as part of combination therapy (e.g., Kligman formula with hydroquinone and a corticosteroid); not FDA-approved for this use. Evidence quality: Moderate (extensive clinical experience).
Flat warts (verrucae planae) — Tretinoin promotes epidermal turnover, potentially dislodging superficial viral lesions. Evidence quality: Low.
Striae (stretch marks) — Some evidence for improvement in early striae rubrae. Limited efficacy in mature striae albae. Evidence quality: Low.
Tretinoin Topical Dosing
Dosing — By Indication and Formulation
| Clinical Scenario | Formulation | Dose | Key Instructions |
|---|---|---|---|
| Acne vulgaris — standard | Retin-A Cream 0.025%, 0.05%, or 0.1%; Gel 0.01% or 0.025% | Apply once daily in the evening | Cleanse face, pat dry; apply thin layer to entire affected area Start with lowest strength and titrate up based on tolerance; expect initial worsening (retinisation) |
| Acne vulgaris — microsponge | Retin-A Micro 0.04%, 0.06%, 0.08%, or 0.1% gel | Apply once daily in the evening | MICROSPONGE system delivers tretinoin gradually, reducing irritation vs conventional formulations Lower irritation profile than Retin-A Cream at equivalent strength (confirmed in half-face trial, PI) |
| Acne vulgaris — lotion | Altreno 0.05% lotion | Apply once daily in the evening | Approved for patients ≥9 years of age Lotion vehicle with hyaluronic acid; may be better tolerated on dry or sensitive skin |
| Fine facial wrinkles (photoaging) | Renova 0.02% or 0.05% cream | Apply once daily in the evening | Pea-sized amount (~5 mm diameter) for entire face; wait 20–30 min after washing before applying Part of a comprehensive skin care program with SPF ≥15 sunscreen, protective clothing, and sunlight avoidance; up to 6 months for visible improvement; safety >52 weeks not established |
During the first 2–4 weeks of tretinoin therapy, patients typically experience an apparent worsening of acne (purging) along with dryness, peeling, and erythema. This is a normal pharmacological response resulting from the action of tretinoin on deep, previously unseen lesions. Advise patients that this initial flare does not indicate treatment failure. Cutaneous irritation scores peak during the initial 2 weeks and then decrease. If irritation is intolerable, reduce application frequency (every other night) or switch to a lower strength rather than discontinuing entirely. Using a non-comedogenic moisturiser 20–30 minutes after tretinoin application can significantly improve tolerance.
Pharmacology
Mechanism of Action
Tretinoin is all-trans-retinoic acid, a naturally occurring metabolite of vitamin A that activates all three retinoic acid receptor (RAR) subtypes: RARα, RARβ, and RARγ. These nuclear receptors function as ligand-dependent transcription factors that regulate gene expression governing epithelial cell growth and differentiation. In acne, tretinoin decreases the cohesiveness of follicular epithelial cells, reducing microcomedo formation, and stimulates increased mitotic activity and turnover of follicular epithelial cells, causing extrusion of existing comedones. In photoaged skin, tretinoin promotes new collagen formation in the papillary dermis, restores epidermal thickness and normal morphology, disperses melanin granules, and increases epidermal–dermal anchoring fibrils. However, the PI notes that it has not been definitively established whether the clinical effects of tretinoin are mediated solely through RAR activation.
ADME Profile
| Parameter | Value | Clinical Implication |
|---|---|---|
| Absorption | Minimal systemic absorption; in vivo bioavailability 0.82% (single dose) to 1.41% (multiple applications over 28 days) for Retin-A Micro 0.1%; Renova 0.05%: percutaneous absorption <2%, with less absorption after repeated application vs single dose (Retin-A Micro PI; Renova PI) | Endogenous tretinoin levels are not meaningfully altered by topical application; systemic retinoid effects are not expected at therapeutic topical doses |
| Distribution | Tretinoin is an endogenous compound; plasma concentrations of tretinoin and metabolites range from 1–3 ng/mL and are essentially unaltered from baseline after topical application (Retin-A Micro PI) | Topical tretinoin does not raise systemic retinoid levels above the normal physiological range |
| Metabolism | Tretinoin is metabolised to 13-cis-retinoic acid (isotretinoin), all-trans-4-oxo-retinoic acid, and 13-cis-4-oxo-retinoic acid; all are endogenous vitamin A metabolites (Retin-A Micro PI) | No CYP-mediated drug interactions expected; metabolites are normal components of vitamin A physiology |
| Elimination | Tretinoin and metabolites are eliminated via normal vitamin A metabolic pathways; no specific renal or hepatic elimination data for topical formulations due to negligible absorption (PI) | No dose adjustment required in renal or hepatic impairment; accumulation is not a clinical concern |
Side Effects
| Adverse Effect | Incidence | Clinical Note |
|---|---|---|
| Cutaneous irritation (composite: dryness, peeling, erythema, burning/stinging, itching) | ~50% at Week 2 (0.04% gel); majority of patients experience some degree (FDA PI) | Expected pharmacological response; peaks during initial 2 weeks then decreases; most mild in severity (63% mild, 34% moderate in 12-week comparative trial) |
| Skin and subcutaneous tissue AEs (overall category) | 15% (0.04%) to 21% (0.1%) in 12-week trial (FDA PI) | Directly proportional to tretinoin concentration; higher strengths produce more irritation but not necessarily better acne outcomes |
| Adverse Effect | Incidence (0.1%) | Incidence (0.04%) | Clinical Note |
|---|---|---|---|
| Skin burning | 8% | — | Transient; peaks in first 2 weeks |
| Erythema | 5% | — | Dose-dependent; may require temporary reduction in frequency |
| Skin irritation | 4% | 6% | Most prevalent AE in the 0.04% group |
| Dermatitis | 4% | — | Contact irritant rather than allergic in most cases; true contact allergy to tretinoin is rare |
| Adverse Effect | Estimated Frequency | Typical Onset | Required Action |
|---|---|---|---|
| Severe blistering / crusting | Rare (≤3% severe irritation with 0.1%; 4 patients with blistering within 3–5 days, from PI) | Within first week of treatment, especially at 0.1% strength | Discontinue immediately until skin integrity is restored; restart at lower strength or frequency when healed |
| Photosensitivity / severe sunburn | Heightened susceptibility during treatment (PI warning) | Throughout treatment duration | Strict sunscreen use (SPF ≥15); protective clothing; do not apply to sunburned skin; avoid concurrent photosensitising drugs (Renova PI) |
| Hyper- or hypopigmentation | ~2% of post-marketing reports for Renova 0.05% (FDA PI) | With repeated application; may persist after discontinuation | Reported as reversible upon discontinuation per PI; counsel patients with darker skin tones about risk; consider lower strength |
Retin-A Gel and generic tretinoin gel formulations contain alcohol and are flammable. Keep away from heat, flame, and smoking during use. This warning applies to all alcohol-containing gel vehicles. The cream, lotion, and microsponge gel formulations are not flammable.
Drug Interactions
No formal drug interaction studies have been conducted with topical tretinoin. Because systemic absorption is negligible, pharmacokinetic interactions with oral medications are not expected. However, several topical product interactions are clinically important due to additive irritation and photosensitisation effects.
Monitoring
-
Skin Tolerance
Weeks 2, 4, 8, 12
Routine Assess erythema, peeling, dryness, burning/stinging, and itching severity. Irritation peaks at Week 2 and should decrease with continued use. If excessive redness, edema, blistering, or crusting occurs, reduce frequency or strength, or temporarily discontinue. -
Acne Response
8–12 weeks
Routine Visible improvement may begin after 2 weeks, but more than 7 weeks are usually needed for consistent benefit. An initial apparent worsening (purging) during the first 2–4 weeks is expected and is not a reason to discontinue. If no improvement after 12 weeks of consistent use, reassess diagnosis and consider alternative or combination therapy. -
Pigmentation
Ongoing
Routine Monitor for hyper- or hypopigmentation, especially in patients with Fitzpatrick skin types III–VI. Pigmentary changes have been reported with repeated application and may be temporary or persistent. Use strict sun protection to minimise risk. -
Pregnancy Status
Before initiation (Renova)
Trigger-based Renova PI states the product should NOT be used during pregnancy or in women attempting to become pregnant. For acne formulations: human observational data have not established a drug-associated risk, but animal teratogenicity has been demonstrated. Discuss contraception as clinically appropriate.
Contraindications & Cautions
Absolute Contraindications
- Hypersensitivity to tretinoin or any component of the formulation
Additional Contraindications (Renova Specifically)
- Pregnancy or attempting to become pregnant
- Sunburn — do not apply until fully recovered
- Eczema or other chronic facial skin conditions
- Inherent photosensitivity
- Concurrent use of photosensitising drugs (thiazides, tetracyclines, fluoroquinolones, phenothiazines, sulfonamides)
Use with Caution
- Eczematous skin — tretinoin can cause severe irritation on eczematous skin (all formulations)
- Extreme weather — severe wind or cold increases risk of irritation
- Application near eyes, mouth, paranasal creases, and mucous membranes — avoid contact with these areas
- Broken or abraded skin — increased absorption and irritation risk
Animal studies in hairless albino mice suggest that tretinoin may enhance the tumorigenic potential of carcinogenic doses of UV radiation. This has been confirmed in pigmented mice, where dark pigmentation did not overcome the enhancement of photocarcinogenesis by 0.05% tretinoin. The clinical significance for humans is not established. Nevertheless, patients should minimise exposure to sunlight and artificial UV sources during treatment, and use comprehensive sun protection (SPF ≥15 sunscreen, protective clothing) at all times.
Patient Counselling
Purpose of Therapy
Tretinoin is a prescription-strength vitamin A derivative applied to the skin. For acne, it works by promoting skin cell turnover to unclog pores and prevent new blemishes from forming. For fine wrinkles, it gradually improves skin texture over months of use. It is applied as a thin layer to the entire affected area once daily in the evening.
Sources
- Retin-A (tretinoin) cream, gel, liquid. Full Prescribing Information. Bausch Health US, LLC. NDA 016921. FDA Label Primary source for Retin-A formulations (cream 0.025/0.05/0.1%, gel 0.01/0.025%), mechanism of action, flammability warning, and pregnancy category C.
- Retin-A Micro (tretinoin) gel, for topical use. Full Prescribing Information. Bausch Health US, LLC. NDA 020475. Revised 2025. FDA Label Source for microsponge gel (0.04–0.1%), PK data (bioavailability 0.82–1.41%, plasma levels 1–3 ng/mL), AE incidence from 12-week trials, and updated pregnancy data (no association in observational studies).
- Renova (tretinoin cream) 0.02%. Full Prescribing Information. Bausch Health US, LLC. NDA 021108. Revised 2014. FDA Label Source for photoaging indication, percutaneous absorption (<2%), photocarcinogenicity data in mice, and Renova-specific contraindications including pregnancy and photosensitising drugs.
- Altreno (tretinoin) lotion 0.05%. Full Prescribing Information. Ortho Dermatologics. NDA 209353. Approved 2018. FDA Label Source for lotion formulation approved for acne ≥9 years; includes animal reproductive toxicity data (craniofacial abnormalities at 2× MRHD in rats).
- Zaenglein AL, Pathy AL, Schlosser BJ, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2016;74(5):945-973.e33. doi:10.1016/j.jaad.2015.12.037 AAD evidence-based guidelines recommending topical retinoids (including tretinoin) as first-line for comedonal acne and as maintenance therapy; strong recommendation with high-quality evidence.
- Leyden J, Stein-Gold L, Weiss J. Why topical retinoids are the mainstay of therapy for acne. Dermatol Ther (Heidelb). 2017;7(3):293-304. doi:10.1007/s13555-017-0185-2 Expert review explaining the central role of retinoids in targeting the microcomedo, the precursor lesion of all acne subtypes.
- Mukherjee S, Date A, Patravale V, Korting HC, Roeder A, Weindl G. Retinoids in the treatment of skin aging: an overview of clinical efficacy and safety. Clin Interv Aging. 2006;1(4):327-348. doi:10.2147/ciia.2006.1.4.327 Comprehensive review of tretinoin’s effects on photodamaged skin: new collagen formation, epidermal restoration, melanin dispersion, and increased anchoring fibrils.
- Kang S, Duell EA, Fisher GJ, et al. Application of retinol to human skin in vivo induces epidermal hyperplasia and cellular retinoid binding proteins characteristic of retinoic acid but without measurable retinoic acid levels or irritation. J Invest Dermatol. 1995;105(4):549-556. doi:10.1111/1523-1747.ep12323445 Foundational study differentiating retinol and retinoic acid effects on skin; supports the mechanistic basis for tretinoin’s clinical activity via RAR pathways.
- Shalita AR, Chalker DK, Griffith RF, et al. Tazarotene gel is safe and effective in the treatment of acne vulgaris: a multicenter, double-blind, vehicle-controlled study. Cutis. 1999;63(6):349-354. Comparative context for retinoid class tolerability in acne; supports the established side effect profile of retinoid-induced cutaneous irritation.
- Loureiro KD, Kao KK, Jones KL, et al. Minor malformations characteristic of the retinoic acid embryopathy and other birth outcomes in children of women exposed to topical tretinoin during early pregnancy. Am J Med Genet A. 2005;136(2):117-121. doi:10.1002/ajmg.a.30744 Key epidemiological study finding no increased risk of retinoic acid embryopathy-type malformations after first-trimester topical tretinoin exposure; supports the human safety data cited in the 2025 Retin-A Micro PI.
- Jick SS, Terris BZ, Jick H. First trimester topical tretinoin and congenital disorders. Lancet. 1993;341(8854):1181-1182. doi:10.1016/0140-6736(93)91013-C Early epidemiological study of topical tretinoin in pregnancy; no significant increase in birth defects identified, supporting the low systemic exposure hypothesis.